CELZ
NASDAQ · Biotechnology
Creative Medical Technology
$1.93
+0.15 (+8.43%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 760.8K | 749.0K | 753.7K |
| Net Income | -122,856 | -154,552 | -129,649 |
| EPS | — | — | — |
| Profit Margin | -16.2% | -20.6% | -17.2% |
| Rev Growth | +19.4% | +1.8% | -1.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 743.5K | 572.6K | 615.2K |
| Total Equity | 3.26M | 3.37M | 3.00M |
| D/E Ratio | 0.23 | 0.17 | 0.21 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -142,343 | -155,667 | -163,320 |
| Free Cash Flow | -180,689 | -141,548 | -126,501 |